Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes

Madeline Nieves-Cintrón, Daniel Caballero-Rivera, Manuel F Navedo, José A. Lasalde-Dominicci

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The second transmembrane domain (TMD2) of the Cys-loop family of ligand-gated ion channels forms the channel pore. The functional role of the amino acid residues contributing to the channel pore in neuronal nicotinic α3 receptors is not well understood. We characterized the contribution of TMD2 position V7′ to channel gating in neuronal nicotinic α3 receptors. Site-directed mutagenesis was used to substitute position α3 (V7′) with four different amino acids (A, F, S, or Y) and coexpressed each mutant subunit with wild-type (WT) β2 or β4 subunits in Xenopus oocytes. Whole-cell voltage clamp experiments show that substitution for an alanine, serine, or phenylalanine decreased by 2.3-6.2-fold the ACh-EC 50 for α3β2 and α3β4 receptor subtypes. Interestingly, mutation V7′Y did not produce a significant change in ACh-EC50 when coexpressed with the β2 subunit but showed a significant approximately two-fold increase with β4. Similar responses were obtained with nicotine as the agonist. The antagonist sensitivity of the mutant channels was assessed by using dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA). The apparent potency of DHβE as an antagonist increased by ∼3.7- and 11-fold for the α3β2 V7′S and V7′F mutants, respectively, whereas no evident changes in antagonist potency were observed for the V7′A and V7′Y mutants. The V7′S and V7′F mutations increase MLA antagonist potency for the α3β4 receptor by ∼6.2- and ∼9.3-fold, respectively. The V7′A mutation selectively increases the MLA antagonist potency for the α3β4 receptor by ∼18.7-fold. These results indicate that position V7′ contributes to channel gating kinetics and pharmacology of the neuronal nicotinic α3 receptors.

Original languageEnglish (US)
Pages (from-to)1778-1788
Number of pages11
JournalJournal of Neuroscience Research
Volume84
Issue number8
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Valine
Nicotinic Receptors
Mutation
Ligand-Gated Ion Channels
Amino Acids
Xenopus
Site-Directed Mutagenesis
Phenylalanine
Nicotine
Alanine
Serine
Oocytes
Pharmacology
methyllycaconitine

Keywords

  • Acetylcholine
  • AChR
  • Nicotine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes. / Nieves-Cintrón, Madeline; Caballero-Rivera, Daniel; Navedo, Manuel F; Lasalde-Dominicci, José A.

In: Journal of Neuroscience Research, Vol. 84, No. 8, 12.2006, p. 1778-1788.

Research output: Contribution to journalArticle

Nieves-Cintrón, M, Caballero-Rivera, D, Navedo, MF & Lasalde-Dominicci, JA 2006, 'Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes', Journal of Neuroscience Research, vol. 84, no. 8, pp. 1778-1788. https://doi.org/10.1002/jnr.21085
Nieves-Cintrón, Madeline ; Caballero-Rivera, Daniel ; Navedo, Manuel F ; Lasalde-Dominicci, José A. / Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes. In: Journal of Neuroscience Research. 2006 ; Vol. 84, No. 8. pp. 1778-1788.
@article{48cfffdf288b41aaa30b681ccb7fd622,
title = "Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes",
abstract = "The second transmembrane domain (TMD2) of the Cys-loop family of ligand-gated ion channels forms the channel pore. The functional role of the amino acid residues contributing to the channel pore in neuronal nicotinic α3 receptors is not well understood. We characterized the contribution of TMD2 position V7′ to channel gating in neuronal nicotinic α3 receptors. Site-directed mutagenesis was used to substitute position α3 (V7′) with four different amino acids (A, F, S, or Y) and coexpressed each mutant subunit with wild-type (WT) β2 or β4 subunits in Xenopus oocytes. Whole-cell voltage clamp experiments show that substitution for an alanine, serine, or phenylalanine decreased by 2.3-6.2-fold the ACh-EC 50 for α3β2 and α3β4 receptor subtypes. Interestingly, mutation V7′Y did not produce a significant change in ACh-EC50 when coexpressed with the β2 subunit but showed a significant approximately two-fold increase with β4. Similar responses were obtained with nicotine as the agonist. The antagonist sensitivity of the mutant channels was assessed by using dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA). The apparent potency of DHβE as an antagonist increased by ∼3.7- and 11-fold for the α3β2 V7′S and V7′F mutants, respectively, whereas no evident changes in antagonist potency were observed for the V7′A and V7′Y mutants. The V7′S and V7′F mutations increase MLA antagonist potency for the α3β4 receptor by ∼6.2- and ∼9.3-fold, respectively. The V7′A mutation selectively increases the MLA antagonist potency for the α3β4 receptor by ∼18.7-fold. These results indicate that position V7′ contributes to channel gating kinetics and pharmacology of the neuronal nicotinic α3 receptors.",
keywords = "Acetylcholine, AChR, Nicotine",
author = "Madeline Nieves-Cintr{\'o}n and Daniel Caballero-Rivera and Navedo, {Manuel F} and Lasalde-Dominicci, {Jos{\'e} A.}",
year = "2006",
month = "12",
doi = "10.1002/jnr.21085",
language = "English (US)",
volume = "84",
pages = "1778--1788",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Contribution of valine 7′ of TMD2 to gating of neuronal α3 receptor subtypes

AU - Nieves-Cintrón, Madeline

AU - Caballero-Rivera, Daniel

AU - Navedo, Manuel F

AU - Lasalde-Dominicci, José A.

PY - 2006/12

Y1 - 2006/12

N2 - The second transmembrane domain (TMD2) of the Cys-loop family of ligand-gated ion channels forms the channel pore. The functional role of the amino acid residues contributing to the channel pore in neuronal nicotinic α3 receptors is not well understood. We characterized the contribution of TMD2 position V7′ to channel gating in neuronal nicotinic α3 receptors. Site-directed mutagenesis was used to substitute position α3 (V7′) with four different amino acids (A, F, S, or Y) and coexpressed each mutant subunit with wild-type (WT) β2 or β4 subunits in Xenopus oocytes. Whole-cell voltage clamp experiments show that substitution for an alanine, serine, or phenylalanine decreased by 2.3-6.2-fold the ACh-EC 50 for α3β2 and α3β4 receptor subtypes. Interestingly, mutation V7′Y did not produce a significant change in ACh-EC50 when coexpressed with the β2 subunit but showed a significant approximately two-fold increase with β4. Similar responses were obtained with nicotine as the agonist. The antagonist sensitivity of the mutant channels was assessed by using dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA). The apparent potency of DHβE as an antagonist increased by ∼3.7- and 11-fold for the α3β2 V7′S and V7′F mutants, respectively, whereas no evident changes in antagonist potency were observed for the V7′A and V7′Y mutants. The V7′S and V7′F mutations increase MLA antagonist potency for the α3β4 receptor by ∼6.2- and ∼9.3-fold, respectively. The V7′A mutation selectively increases the MLA antagonist potency for the α3β4 receptor by ∼18.7-fold. These results indicate that position V7′ contributes to channel gating kinetics and pharmacology of the neuronal nicotinic α3 receptors.

AB - The second transmembrane domain (TMD2) of the Cys-loop family of ligand-gated ion channels forms the channel pore. The functional role of the amino acid residues contributing to the channel pore in neuronal nicotinic α3 receptors is not well understood. We characterized the contribution of TMD2 position V7′ to channel gating in neuronal nicotinic α3 receptors. Site-directed mutagenesis was used to substitute position α3 (V7′) with four different amino acids (A, F, S, or Y) and coexpressed each mutant subunit with wild-type (WT) β2 or β4 subunits in Xenopus oocytes. Whole-cell voltage clamp experiments show that substitution for an alanine, serine, or phenylalanine decreased by 2.3-6.2-fold the ACh-EC 50 for α3β2 and α3β4 receptor subtypes. Interestingly, mutation V7′Y did not produce a significant change in ACh-EC50 when coexpressed with the β2 subunit but showed a significant approximately two-fold increase with β4. Similar responses were obtained with nicotine as the agonist. The antagonist sensitivity of the mutant channels was assessed by using dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA). The apparent potency of DHβE as an antagonist increased by ∼3.7- and 11-fold for the α3β2 V7′S and V7′F mutants, respectively, whereas no evident changes in antagonist potency were observed for the V7′A and V7′Y mutants. The V7′S and V7′F mutations increase MLA antagonist potency for the α3β4 receptor by ∼6.2- and ∼9.3-fold, respectively. The V7′A mutation selectively increases the MLA antagonist potency for the α3β4 receptor by ∼18.7-fold. These results indicate that position V7′ contributes to channel gating kinetics and pharmacology of the neuronal nicotinic α3 receptors.

KW - Acetylcholine

KW - AChR

KW - Nicotine

UR - http://www.scopus.com/inward/record.url?scp=33845407238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845407238&partnerID=8YFLogxK

U2 - 10.1002/jnr.21085

DO - 10.1002/jnr.21085

M3 - Article

C2 - 17044037

AN - SCOPUS:33845407238

VL - 84

SP - 1778

EP - 1788

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 8

ER -